Aileron Therapeutics, Inc. (ALRN)

Aileron Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	17.34	5.22	3.63	7.64	5.34
Short-Term Investments	0	16.05	42.33	6.76	12.97
Cash & Cash Equivalents	17.34	21.27	45.96	14.4	18.3
Cash Growth	-18.47%	-53.73%	219.20%	-21.34%	-11.67%
Other Current Assets	0.93	0.61	2.22	1.93	1.25
Total Current Assets	18.27	21.87	48.18	16.33	19.55
Property, Plant & Equipment	0.02	0.11	0.28	0.02	6.36
Long-Term Investments	0	0	0	0	0.57
Goodwill and Intangibles	85.53	0	0	0	0
Other Long-Term Assets	2.19	0.02	0.02	0	0
Total Long-Term Assets	87.74	0.13	0.3	0.02	6.92
Total Assets	106.01	22.01	48.48	16.34	26.47
Accounts Payable	1.19	1.72	1.21	1.6	1.45
Current Debt	0.05	0.03	0.09	0.17	0.45
Other Current Liabilities	3.15	1.63	3.21	2.2	3.94
Total Current Liabilities	4.39	3.38	4.51	3.96	5.84
Long-Term Debt	0	0	0.07	0.22	4.59
Other Long-Term Liabilities	3.33	0	0	0	0
Total Long-Term Liabilities	3.33	0	0.07	0.22	4.59
Total Liabilities	7.71	3.38	4.58	4.18	10.43
Total Debt	0.05	0.03	0.16	0.39	5.03
Debt Growth	45.45%	-79.63%	-58.14%	-92.31%	-5.80%
Retained Earnings	-288.52	-272.79	-245.46	-219.29	-198.14
Comprehensive Income	-0.06	-0.05	-0.01	-0	0.01
Shareholders' Equity	98.3	18.62	43.9	12.16	16.05
Net Cash / Debt	17.29	21.23	45.8	14.01	13.27
Net Cash / Debt Growth	-18.57%	-53.63%	226.86%	5.58%	-13.70%
Net Cash Per Share	3.76	4.68	10.31	8.04	10.82
Working Capital	13.88	18.49	43.67	12.37	13.71
Book Value Per Share	21.38	4.10	9.89	6.98	13.08

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).